Haemostasis October 2024 Journal Club

Keep informed about evolving science and clinical practice with our October 2024 compilation of the latest studies, guidelines, and perspectives in haemostasis.

GUIDELINES

• Baker P, Platton S, Arachchillage DJ, et al. Measurement of heparin, direct oral anti-coagulants and other non-coumarin anti-coagulants and their effects on haemostasis assays: A British Society for Haematology Guideline. Br J Haematol. 2024;205(4). doi:10.1111/bjh.19729
• Adcock DM, Moore GW, Kershaw GW, et al. International Council for Standardization in Haematology (ICSH) recommendations for the performance and interpretation of activated partial thromboplastin time and prothrombin time mixing tests.Int J Lab Hematol. 2024;46(5):777-788. doi:10.1111/ijlh.14344

PERSPECTIVES & REVIEWS

• Buka RJ, Pavord S. Anti-platelet factor 4 immunothrombotic syndromes. Br J Haematol. 2024; 205(4):1291–1295. org/10.1111/bjh.19663
• Batran RA, Kamel M, Bahr A, et al. Hemophilia A: Economic burden, therapeutic advances, and future forecasts in the Middle East and North Africa region. Thromb Res. 2024;243:109175. doi:10.1016/j.thromres.2024.109175
• Guduguntla V, Patton KK. Rethinking anticoagulation for left atrial appendage closure. JAMA Cardiol.2024;9(10):927. doi:10.1001/jamacardio.2024.2390
• Leader A, Wilcox JA,  Zwicker JI. How I treat acute venous thromboembolism in patients with brain tumors.Blood 2024;144(17):1781–1790. doi:10.1182/blood.2023023450
• Mathias C, Bouvier S, Gris JC, et al. The hemostatic system in chronic brain diseases: A new challenging frontier? Thromb Res. 2024;243:109154. doi:0.1016/j.thromres.2024.109154
• Žunić M, Vreča N, Bevc S. The role of factor XIII in patient blood management. Blood Coagul Fibrinolysis. 2024;35(7):325-333. doi:10.1097/MBC.0000000000001326

CLINICAL TRIALS

• Breau RH, et al. Tranexamic acid during radical cystectomy: a randomized clinical trial. JAMA Surg 2024; Oct 2 [Online ahead of print]. doi:10.1001/jamasurg.2024.4183
• Freixa X, Cruz-González I, Cepas-Guillén P, et al. Low-dose direct oral anticoagulation vs Dual antiplatelet therapy after left atrial appendage occlusion: The ADALA randomized clinical trial.JAMA Cardiol. 2024;9(10):922–926. doi:10.1001/jamacardio.2024.2335
• Karanicolas PJ, Lin Y, McCluskey SA, et al. Tranexamic acid in patients undergoing liver resection: The HeLiX randomized clinical trial. 2024;332(13):1080–1089. doi:10.1001/jama.2024.11783
• Ker K, Sentilhes L, Shakur-Still H, et al. Tranexamic acid for postpartum bleeding: a systematic review and individual patient data meta-analysis of randomised controlled trials. Lancet 2024; 404;10463:1657-1667.doi:10.1016/S0140-6736(24)02102-0
• Lamy A, Sirota DA, Jacques F, et al. Topical versus intravenous tranexamic acid in patients undergoing cardiac surgery: The DEPOSITION randomized controlled trial. 2024; 150(17):1315-1323. doi:10.1161/CIRCULATIONAHA.124.069606
• Palaiodimou L, Katsanos AH, Turc G, et al. Tenecteplase vs Alteplase in acute ischemic stroke within 4.5 hours: A systematic review and meta-analysis of randomized trials.Neurology. 2024;103(9):e209903. doi:10.1212/WNL.0000000000209903
• Pittman DD, Carrieri C, Soares H, et al. Field study and correlative studies of Factor IX variant FIX-R338L in participants treated with Fidanacogene Elaparvovec. Thromb Haemost. 2024; 124(10):912-921. doi:10.1055/s-0044-1787734
• Vriesendorp PA, Nanayakkara S, Heuts S, et al. Routine protamine administration for bleeding in transcatheter aortic valve implantation: The ACE-PROTAVI randomized clinical trial.JAMA Cardiol. 2024;9(10):901–908. doi:10.1001/jamacardio.2024.2454

CASE SERIES & RETROSPECTIVE STUDIES

• Ansteatt KT, Roberts JC, Helms JM, et al. Improved prevention of bleeding episodes with emicizumab in 3 patients with concomitant hemophilia A and von Willebrand disease. Blood Coagul Fibrinolysis. 2024;35(7):340-344. doi:10.1097/MBC.0000000000001324
• Chen X, Zhai Z, Lin L, et al. The role of anticoagulation on the long-term survival of patients with pulmonary arterial hypertension: A meta-analysis of 15 cohort studies. Thromb Res. 2024;243:109173. doi:10.1016/j.thromres.2024.109173
• Chlench S, Freudenthal N. Associations between clinical factors and postoperative thrombosis in pediatric cardiac surgery patients: A single-center retrospective study. Crit Care Explor. 2024;6(10):pe1170. doi:10.1097/CCE.0000000000001170
• Guillet B, Pawlowski M, Boisseau P, et al. Genotype-dependent response to desmopressin in hemophilia A and proposal of a predictive response score. Thromb Haemost. 2024;124(10): 922-936. doi:10.1055/a-2329-3375
• Heubner L, Grottke O, Vicent O, Spieth PM, Beyer-Westendorf J. Monitoring the efficiency of reversal on anti-Xa direct oral anticoagulants using point-of-care viscoelastic testing.Thromb J. 2024;22(1):89. doi:10.1186/s12959-024-00659-8
• Kühne L, Knöbl P, Eller K, et al. Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange.Blood. 2024;144(14):1486-1495. doi:10.1182/blood.2023023780
• Lagano A, Fucci L, Sorella S, et al. Venous thromboembolism secondary prophylaxis in elderly people (over 75-year-old) with low-dose direct oral anticoagulants: single-center Italian experience. Blood Coagul Fibrinolysis. 2024;35(7):334-339. doi:10.1097/MBC.0000000000001321
• Miller W, Braaten J, Rauzi A, et al. Thromboembolic complications in continuous versus interrupted anticoagulation during venovenous extracorporeal membrane oxygenation: A multicenter study. Crit Care Explor. 2024;6(10):e1155. doi:10.1097/CCE.0000000000001155
• Mingot-Castellano ME, Bastida JM, Ghanima W,  et al. Avatrombopag plus fostamatinib combination as treatment in patients with multirefractory immune thrombocytopenia. Br J Haematol. 2024;205(4):1551–1555. doi:10.1111/bjh.19602
• Mohamed A, Shewmaker J, Berry T, et al.The incidence of thrombotic events after the concomitant use of andexanet alfa and 4-factor prothrombin complex concentrate. Hosp Pharm 2024;59:536-543. doi:10.1177/00185787241242759
• Patil T, Ali S, Eppes D, Lee A, Jarmukli N. Evaluating the safety and effectiveness of direct oral anticoagulants compared with warfarin in very elderly patients with atrial fibrillation with and without low bodyweight.J Thromb Haemost. 2024; S1538-7836(24)00428-8. doi:10.1016/j.jtha.2024.07.011
• Shaw JR, Almujalli AA, Xu Y, et al. Prothrombin complex concentrate for direct factor Xa inhibitor-associated bleeding or before urgent surgery. Thromb Res. 2024;243:109172. doi:10.1016/j.thromres.2024.109172
• Utsumi S, et al.Tranexamic acid in pediatric traumatic brain injury: a multicenter retrospective observational study. Ann Emerg Med 2024; Oct 1 [Online ahead of print]. doi:10.1016/j.annemergmed.2024.07.014

RESEARCH

• Battafarano, G, Lancellotti, S, Sacco, M, et al.Effects of coagulation factors on bone cells and consequences of their absence in haemophilia a patients. Sci Rep 2024;14,25001. :10.1038/s41598-024-75747-w
• Chen Z, Zheng Q, Wang Y, et al. CXCL13/CXCR5 axis facilitates TFH expansion and correlates with disease severity in adults with immune thrombocytopenia. Thromb Res. 2024; 244:109196. doi:10.1016/j.thromres.2024.109196
• Feige T, Bosbach A, Krott KJ, et al. GP VI-mediated platelet activation and procoagulant activity aggravate inflammation and aortic wall remodeling in abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol. 2024;44(11):2294-2317. doi:10.1161/ATVBAHA.123.320615
• Hegde S, Akbar H, Wellendorf AM, et al. Inhibition of RHOA activity preserves the survival and hemostasis function of long-term cold-stored platelets.Blood 2024;144 (16):1732–1746. doi:10.1182/blood.2023021453
• Jiang D, Houck KL, Murdiyarso L, et al. RBCs regulate platelet function and hemostasis under shear conditions through biophysical and biochemical means.Blood. 2024;144(14):1521-1531. doi:10.1182/blood.2024023887
• Kaiser R, Dewender R, Mulkers M, et al. Procoagulant platelet activation promotes venous thrombosis.Blood 2024; [Online ahead of print] doi:10.1182/blood.2024025476
• Manikanta, NaveenKumar SK, Thushara RM et al. Counteraction of unconjugated bilirubin against heme-induced toxicity in platelets. Thromb Res, 2024 Oct 23 [Online ahead of print] doi:10.1016/j.thromres.2024.109199
• Puy C, Moellmer SA, Pang J, et al. Coagulation factor XI regulates endothelial cell permeability and barrier function in vitro and in vivo. Blood. 2024;144(17):1821-1833. doi:10.1182/blood.2023022257
• Thaler J, Tripisciano C, Kraemmer D, et al. Saliva from persons with hemophilia A triggers coagulation via extrinsic tenase complexes.Blood doi:10.1182/blood.2024025093
• Üstok FI, Adams TE, Huntington JA. Rapid and ordered cleavage of prothrombin by Hopsarin D in the absence of phospholipid membranes.J Thromb Haemost. 2024;22(11):3070 -3083. doi:10.1016/j.jtha.2024.07.027
• Zhang C, Chen W, Zhang Y, et al. Protein S contributes to the paradoxical increase in thrombin generation by low-dose dabigatran in the presence of thrombomodulin. Blood Coagul Fibrinolysis. 2024;35(7):334-339. doi:10.1097/MBC.0000000000001320

METHODS

• Ajzenberg N, Longrois D, Faille D, et al. Sensitivity and specificity of strategies to identify patients with hemostasis abnormalities leading to an increased risk of bleeding before scheduled intervention: the Hemorisk study.J Thromb Haemost. 2024;22(11):3070 -3083 doi:10.1016/j.jtha.2024.07.024
• Bourguignon A, Mathews N, Tasneem S, et al. Rapid diagnosis of coagulopathies from vitamin K deficiency in a consecutive case cohort evaluated by comparative assessment of factor II by 1-stage assays with prothrombin time vs Ecarin reagents.J Thromb Haemost. 2024;22(11):3070 -3083. doi:10.1016/j.jtha.2024.08.002
• Del Ben F, Fontanini E, Azzarini G, et al. Comparison of four D-dimer assays in the context of venous thromboembolism in the emergency department.Int J Lab Hematol. 2024;46(5):936-945. doi:10.1111/ijlh.14302
• Hardy, M. et al. Development and validation of an in vitro model to study thrombin generation on the surface of catheters in platelet-poor and platelet-rich plasma. Thromb Res. 2024; Oct 18 [Online ahead of print] doi:10.1016/j.thromres.2024.109194
• Klöter T, Metze M, Kunze R, et al. Detection of direct oral anticoagulants with the diluted Russel’s viper venom time.Int J Lab Hematol. 2024;46(5):927-935. doi:10.1111/ijlh.14300
• Melicine S, Habay C, Ghammad W, et al. DOAC-Remove to counteract the interference of anti-Xa oral anticoagulants on the monitoring of heparin. Int J Lab Hematol. 2024;46(5):953-962. doi:10.1111/ijlh.14321
• Røed-Undlien H, Schultz NH, Amundsen EK, et al. Does in vitro hemolysis affect measurements of plasma apixaban concentration by UPLC-MS and anti-Xa assay?Int J Lab Hematol. 2024;46(5):946-952. doi:10.1111/ijlh.14311